Editorial: tenofovir alafenamide fumarate—a new bullet to prevent mother‐to‐child transmission of hepatitis B virus. Authors' reply

Pan, Calvin Q.; Cao, Lihua; Huang, Yan

doi:10.1111/apt.16101

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 15 , 44 , 53 , 54 Preliminary data from the TA PROHM study demonstrating that tenofovir with full schedule HBV vaccination alone may be similarly effective to hepatitis B immune globulin plus tenofovir and full schedule HBV vaccination for prevention of mother-to-child HBV transmission are encouraging 55 though further studies are needed before widespread adoption of this strategy. Tenofovir alafenamide has a higher safety profile than tenofovir disoproxil fumarate (including in pregnancy), would be preferable to tenofovir to reduce adverse event monitoring requirements and costs, 56 however, remains unaffordable in most countries, and is not yet included in WHO guidelines.…”

Section: Strategic Direction 1: Deliver High-quality Evidence-based P...mentioning

confidence: 99%

Pathway to global elimination of hepatitis B: HBV cure is just the first step

et al. 2023

View full text Add to dashboard Cite

Hepatitis B (HBV) is a major cause of global morbidity and mortality, and the leading cause of liver cancer worldwide. Significant advances have recently been made toward the development of a finite HBV treatment that achieves permanent loss of HBsAg and HBV DNA (so-called “HBV cure”), which could provide the means to eliminate HBV as a public health threat. However, the HBV cure is just one step toward achieving WHO HBV elimination targets by 2030, and much work must be done now to prepare for the successful implementation of the HBV cure. In this review, we describe the required steps to rapidly scale-up future HBV cure equitably. We present key actions required for successful HBV cure implementation, integrated within the World Health Organization (WHO) Global Health Sector Strategy (GHSS) 2022–2030 framework. Finally, we highlight what can be done now to progress toward the 2030 HBV elimination targets using available tools to ensure that we are preparing, but not waiting, for the cure.

show abstract

Section: Strategic Direction 1: Deliver High-quality Evidence-based P...mentioning

confidence: 99%

Pathway to global elimination of hepatitis B: HBV cure is just the first step

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Exciting progress has been made in developing LA therapies for treating HBV infection, and these drugs hold great promise for the future of HBV treatment, including long-acting TFV for the prevention of mother-to-child transmission [ 132 , 133 , 134 , 135 ].…”

Section: Long-acting Therapeuticsmentioning

confidence: 99%

Chronic Hepatitis B Infection: New Approaches towards Cure

Ogunnaike,

Das,

Raut

et al. 2023

Biomolecules

View full text Add to dashboard Cite

Chronic hepatitis B virus (HBV) infection leads to the development of cirrhosis and hepatocellular carcinoma. Lifelong treatment with nucleotides/nucleoside antiviral agents is effective at suppressing HBV replication, however, adherence to daily therapy can be challenging. This review discusses recent advances in the development of long-acting formulations for HBV treatment and prevention, which could potentially improve adherence. Promising new compounds that target distinct steps of the virus life cycle are summarized. In addition to treatments that suppress viral replication, curative strategies are focused on the elimination of covalently closed circular DNA and the inactivation of the integrated viral DNA from infected hepatocytes. We highlight promising long-acting antivirals and genome editing strategies for the elimination or deactivation of persistent viral DNA products in development.

show abstract

Editorial: tenofovir alafenamide fumarate—a new bullet to prevent mother‐to‐child transmission of hepatitis B virus. Authors' reply

Abstract: LINKED CONTENT This article is linked to Ding et al and Gish & Elmofti papers. To view these articles, visit https://doi.org/10.1111/apt.16043 and https://doi.org/10.1111/apt.16090

Cited by 2 publications

References 10 publications

Pathway to global elimination of hepatitis B: HBV cure is just the first step

Pathway to global elimination of hepatitis B: HBV cure is just the first step

Chronic Hepatitis B Infection: New Approaches towards Cure

Contact Info

Product

Resources

About